Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2016. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), or Connected Persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes and Transactions
On March 17, 2016, increases in the notional allocation of GSK American Depositary Shares (ADSs) occurred within the GSK 401(K) plan following the revaluation of the cash element of the notional investment. The transactions were executed at a price of $40.74 per ADS.
- Dr M M Slaoui (Director/PDMR): 14 ADSs
- Dr K Slaoui (Connected Person of Dr M M Slaoui): 59 ADSs
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Transaction date: March 17, 2016.
- Transaction price: $40.74 per ADS.
- Transaction type: Notional allocation increase within the GSK 401(K) plan due to cash element revaluation.
- Parties involved: Dr M M Slaoui and his connected person, Dr K Slaoui.